.jpg)
Maxim Group analyst Anthony Vendetti maintained a Buy rating on Viveve Medical Inc (NASDAQ: VIVE) today and set a price target of $9. The company’s shares closed yesterday at $2.89, close to its 52-week low of $2.75.
Vendetti wrote:
“1Q18 revenue of $3.7M, up 21.6% y/y, was significantly below both our estimate of $5.0M and consensus of $4.7M. The company sold 53 systems and 5,400 treatment tips during the quarter..”
According to TipRanks.com, Vendetti is ranked #532 out of 4798 analysts.
Currently, the analyst consensus on Viveve Medical Inc is Strong Buy and the average price target is $9, representing a 211.4% upside.
In a report issued on April 27, Mizuho Securities also maintained a Buy rating on the stock with a $10 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $8.75 and a one-year low of $2.75. Currently, Viveve Medical Inc has an average volume of 288K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Viveve Medical, Inc. engages in the provision of health products. Its activities include development and distribution of women’s health solutions. Its products include non-surgical, non-ablative medical device that remodels collagen and restores vaginal tissue. The company was founded on March 3, 1987 and is headquartered Sunnyvale, CA.
